JPRN-jRCTs042210090
Recruiting
Phase 2
A Multicenter Randomized Phase II trial Investigating The Effect of Polyglycolic Acid Sheet for Prevention of Pancreatic Fistula After Gastrectomy with Prophylactic Lymph Node Dissection
Kodera Yasuhiro0 sites320 target enrollmentOctober 28, 2021
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kodera Yasuhiro
- Enrollment
- 320
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who were planned to undergo curative gastrectomy with D1\+ or more lymp node dissection.
- •Aged 20 years or mroe at the time of registration and written informed consent.
Exclusion Criteria
- •History of gastrectomy.
- •History of pancreatectomy.
- •Active infection in abdominal cavity.
- •Tumor invasion to pancreas.
- •Patients who were planned pancreatectomy.
- •Patients who were planned splenectomy.
- •Emergency surgery.
- •Patients who were suspected to have allergy to polyglycolic acid.
- •Patients who were planned robotic assisted gastrectomy.
- •Ineligible for the study at the physician's assessment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A multicenter randomized phase II trial evaluating the efficacy and safety of intrapericardial left superior pulmonary vein ligation or division for prevention of thrombosis in the stumpmalignant tumor of the lungJPRN-UMIN000036037iigata Chest Surgery Study Group60
Completed
Phase 2
Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapyC92.9Myeloid leukaemia, unspecifiedDRKS00000733niversitätsklinikum Freiburg204
Active, not recruiting
Phase 1
Clinical trial of low-dose decitabine (DAC) administered alone or in combination with the valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for standard chemotherapyEUCTR2009-009916-33-DEniversity Medical Center Freiburg200
Not yet recruiting
Phase 2
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck CancerOral MucositisHead and Neck CancerCancer - Head and neckOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12620000540910PSI CRO Australia Pty. Ltd.110
Active, not recruiting
Phase 1
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyEUCTR2024-000203-67-Outside-EU/EEAKadmon Corporation, LLC